ICH M4Q(R2): How the Revised CTD Quality Structure Will Reshape Module 2.3 and Module 3

For more than two decades, the quality part of the Common Technical Document has followed the structure set by ICH M4Q. Its revision, M4Q(R2), changes the logic of the dossier: Module 2.3 moves from a retrospective summary to the main basis of assessment, and Module 3 becomes the supporting body of data. The final text is not yet adopted, but companies planning dossiers for the end of the decade should start thinking in the new structure now.

Where the guideline stands

The ICH Assembly endorsed M4Q(R2) as a Step 2 draft in May 2025, and regional public consultations ran into early 2026, generating a large volume of comments. The Expert Working Group is now working through those comments, with Step 4 adoption targeted for mid-2027. No region has yet set a date from which the new structure becomes mandatory, and ICH is expected to recommend a transition period after adoption.

One practical dependency is already clear: the new headings are designed for eCTD v4.0 and are not expected to be available in eCTD v3.2.2. The timing of M4Q(R2) is therefore tied to each region’s eCTD v4.0 roadmap.

What changes in the structure

  • Module 2.3 becomes the core of the assessment. Instead of summarising Module 3, it presents the product, its overall development and control strategy and its core quality information, and supports lifecycle management.
  • Module 3 becomes the repository. Detailed methods, data and reports sit in Module 3 and support the statements made in Module 2.3.
  • A common pattern for materials. Most subsections follow a description, manufacture, control and storage sequence, applied consistently across the active substance, the drug product and other materials.
  • Regional information is separated. Region-specific content is expected to sit in an addendum alongside the harmonised text rather than inside it.

The guideline changes where information sits and how it is presented. It is not intended to change the underlying regulatory requirements for quality data.

Why it matters for lifecycle management

The revision is designed to work with the science- and risk-based tools of ICH Q8 to Q12 and with structured data. ICH has also endorsed a separate topic, M16, on structured product quality submissions, which will define how parts of Modules 2.3 and 3 can be submitted as data rather than documents. A Module 2.3 that clearly identifies the core quality information and control strategy should make post-approval changes easier to assess and to classify.

What to do before Step 4

  • Map a current product dossier against the draft structure to see where content would move
  • Review whether your Module 2.3 today genuinely explains the control strategy, or only restates Module 3
  • Align authoring templates and document management with eCTD v4.0 planning
  • Track the final text and regional implementation dates rather than restructuring live dossiers prematurely

How PQRA helps

PQRA supports companies with CTD quality authoring, Module 2.3 and Module 3 gap analyses, eCTD lifecycle management and submission planning for EOF and EU procedures. We can help you assess what M4Q(R2) will mean for your portfolio and plan the transition at the right time.

Contact PQRA to plan your CTD quality transition

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *